Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

62462 1502285060HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

J&J's Imbruvica thumps GSK's Arzerra in head-to-head leukemia trial

02.06.2014 / Fierce Pharma

Results are in from a showdown between chronic lymphocytic leukemia drugs Imbruvica, from Johnson & Johnson's Janssen unit, and GlaxoSmithKline's Arzerra. And as it turns out, it wasn't much of a contest.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: